Posted by Michael Wonder on 16 Feb 2019
Innocrin Pharmaceuticals granted fast track designation by FDA for VT-464 treatment of patients with metastatic castrate-resistant prostate cancer
6 January 2016 - Seviteronel to be presented in three sessions at the ASCO Genitourinary Cancer Symposium to be held in San Francisco, California January 7-9, 2016.
Innocrin Pharmaceuticals today announced that the FDA granted fast track designation for seviteronel (VT464) for the treatment of patients with metastatic castrate-resistant prostate cancer.
Read Innocrin Pharmaceuticals press release
